[
  {
    "ts": null,
    "headline": "Top Research Reports for Alphabet, IBM & Merck",
    "summary": "Alphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges.",
    "url": "https://finnhub.io/api/news?id=ace2d271990368c132ebd8efc2c1ea51206f58801aba75b7c1fb5abd78aee0b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758058920,
      "headline": "Top Research Reports for Alphabet, IBM & Merck",
      "id": 136787545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Alphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges.",
      "url": "https://finnhub.io/api/news?id=ace2d271990368c132ebd8efc2c1ea51206f58801aba75b7c1fb5abd78aee0b3"
    }
  },
  {
    "ts": null,
    "headline": "Where is Merck & Co. (MRK) Headed According to Analysts?",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best drug stocks to buy right now. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating. The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position in […]",
    "url": "https://finnhub.io/api/news?id=025f4ec09ac03423a4017deccaf9ef17a40da4706802480571e64aa1c5cb65e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052701,
      "headline": "Where is Merck & Co. (MRK) Headed According to Analysts?",
      "id": 136782171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best drug stocks to buy right now. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating. The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position in […]",
      "url": "https://finnhub.io/api/news?id=025f4ec09ac03423a4017deccaf9ef17a40da4706802480571e64aa1c5cb65e7"
    }
  },
  {
    "ts": null,
    "headline": "UK ‘difficult’ operating environment says Merck boss after £1bn London site axed",
    "summary": "Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.",
    "url": "https://finnhub.io/api/news?id=7010f2d81cf060204173b9b3bc67b62c58a3d09ed33d511562b3f997957ccee8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758043562,
      "headline": "UK ‘difficult’ operating environment says Merck boss after £1bn London site axed",
      "id": 136773383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.",
      "url": "https://finnhub.io/api/news?id=7010f2d81cf060204173b9b3bc67b62c58a3d09ed33d511562b3f997957ccee8"
    }
  },
  {
    "ts": null,
    "headline": "39 Reader Faves Tap 9 Ideal \"Safer\" Dividends In August",
    "summary": "This article emphasizes a contrarian, yield-based strategy, encouraging readers to 'Be More Dog' and use these stocks as research starting points, not recommendations. Read it here.",
    "url": "https://finnhub.io/api/news?id=94f226f06d0d52b281d5db53ef004e8ba186ffc4e1d6424ce0a0f126c8c0b2e9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758042026,
      "headline": "39 Reader Faves Tap 9 Ideal \"Safer\" Dividends In August",
      "id": 136782956,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/931250842/image_931250842.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "This article emphasizes a contrarian, yield-based strategy, encouraging readers to 'Be More Dog' and use these stocks as research starting points, not recommendations. Read it here.",
      "url": "https://finnhub.io/api/news?id=94f226f06d0d52b281d5db53ef004e8ba186ffc4e1d6424ce0a0f126c8c0b2e9"
    }
  },
  {
    "ts": null,
    "headline": "MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer",
    "summary": "Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.",
    "url": "https://finnhub.io/api/news?id=2295b25cd6213388d0d465383b3c8286fd0818cfff2954fca665ad0c1dc085fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758039540,
      "headline": "MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer",
      "id": 136781314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.",
      "url": "https://finnhub.io/api/news?id=2295b25cd6213388d0d465383b3c8286fd0818cfff2954fca665ad0c1dc085fd"
    }
  },
  {
    "ts": null,
    "headline": "Resilience in Healthcare: How Merck (MRK) Maintains Consistent Dividends Through Market Uncertainty",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 13 Best Consistent Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical firms, faces investor concerns as key patents near expiration and much of its revenue depends on its cancer drug Keytruda. While such challenges are common in the industry, […]",
    "url": "https://finnhub.io/api/news?id=c8f97e980daabf6ef6368c9911f5d495487f09ccb64609115b7b19d5ed32af8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758034906,
      "headline": "Resilience in Healthcare: How Merck (MRK) Maintains Consistent Dividends Through Market Uncertainty",
      "id": 136773384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 13 Best Consistent Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical firms, faces investor concerns as key patents near expiration and much of its revenue depends on its cancer drug Keytruda. While such challenges are common in the industry, […]",
      "url": "https://finnhub.io/api/news?id=c8f97e980daabf6ef6368c9911f5d495487f09ccb64609115b7b19d5ed32af8c"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=4fb3bcba88783ffa8a71219befdf23998798c0dccea48a49528d61b3a087c1e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758033003,
      "headline": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?",
      "id": 136773385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=4fb3bcba88783ffa8a71219befdf23998798c0dccea48a49528d61b3a087c1e7"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Buy This Dividend Powerhouse While It's Cheap",
    "summary": "Read why Merck stock is a top pick for long-term investors, offering a 4% dividend yield, robust growth pipeline, and strong earnings outlook.",
    "url": "https://finnhub.io/api/news?id=edefb3c7cf3fca4a1d950baeced5bb7c2797df33fa7487aa453e6b7d1dce115e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758028968,
      "headline": "Merck: Buy This Dividend Powerhouse While It's Cheap",
      "id": 136774695,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read why Merck stock is a top pick for long-term investors, offering a 4% dividend yield, robust growth pipeline, and strong earnings outlook.",
      "url": "https://finnhub.io/api/news?id=edefb3c7cf3fca4a1d950baeced5bb7c2797df33fa7487aa453e6b7d1dce115e"
    }
  },
  {
    "ts": null,
    "headline": "6 Top Stocks For A Fed Rate Cut",
    "summary": "Fed rate cuts are expected as labor data worsens. SA Quant has selected six stocksâthree small-caps and three dividend payersâprimed to benefit.",
    "url": "https://finnhub.io/api/news?id=cdf7298d6eeb64c3dc32b4a8e5217b24bebc884d9af43c9411059a9a4b344b16",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757998800,
      "headline": "6 Top Stocks For A Fed Rate Cut",
      "id": 136771285,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1161083067/image_1161083067.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Fed rate cuts are expected as labor data worsens. SA Quant has selected six stocksâthree small-caps and three dividend payersâprimed to benefit.",
      "url": "https://finnhub.io/api/news?id=cdf7298d6eeb64c3dc32b4a8e5217b24bebc884d9af43c9411059a9a4b344b16"
    }
  }
]